P. McLeroth

发表

Status asthmaticus: a large MICU experience

J. Shapiro, P. McLeroth, 2002 .

Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.

R. Wunderink, M. Niederman, B. Cao, 2019, The Lancet. Infectious diseases.

Prospective, randomized, double‐blind, Phase 2 dose‐ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

N. Kartsonis, A. Pedley, M. Brown, 2017, The Journal of antimicrobial chemotherapy.

FIAU : Human dosimetry and infection imaging in patients with suspected prosthetic joint infection

Steve Y. Cho, A. Alavi, C. Bettegowda, 2017 .

[(124)I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infection.

Steve Y. Cho, A. Alavi, C. Bettegowda, 2016, Nuclear medicine and biology.

A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)

T. File, A. Torres, M. Wilcox, 2018, Antimicrobial Agents and Chemotherapy.

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1

T. File, A. Torres, M. Wilcox, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

D. Venskutonis, D. Sandesc, M. Rizk, 2016, Antimicrobial Agents and Chemotherapy.

Modeling COVID-19 disease biology to identify drug treatment candidates

Adam M. Sullivan, Stefan Díaz Gaisenband, W. Jessen, 2022, bioRxiv.

Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries

K. Saini, Stefan Díaz Gaisenband, P. McLeroth, 2023, Trials.

731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)

A. Dane, G. Moeck, F. Wagenlehner, 2022, Open Forum Infectious Diseases.

A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)

A. Torres, M. Wilcox, T. Holland, 2018, Antimicrobial Agents and Chemotherapy.